N Davis
Novartis
13 Papers
24 Citations
N Davis is an academic researcher from Novartis. The author has contributed to research in topics: Canakinumab & Medicine. The author has an hindex of 8, co-authored 11 publications.
Chat about Author
Papers
Canakinumab treatment for patients with active recurrent or chronic TNF receptor-associated periodic syndrome (TRAPS): an open-label, phase II study
Marco Gattorno,Laura Obici,Marco Cattalini,V. Tormey,Ken Abrams,N Davis,A. Speziale,Suraj G. Bhansali,Alberto Martini,Helen J. Lachmann +9 more
TL;DR: Canakinumab induces rapid disease control in patients with active TRAPS, and clinical benefits are sustained during long-term treatment, and weight normalised pharmacokinetics of canakinumabs appeared to be consistent with historical canakinUMab data.
106
Optimization of the in Vitro Cardiac Safety of Hydroxamate-Based Histone Deacetylase Inhibitors
Michael Shultz,Xueying Cao,Chen Christine Hiu-Tung,Young Shin Cho,N Davis,Joe Eckman,Jianmei Fan,Alex Fekete,Brant Firestone,Julie Flynn,Jack Green,Joseph D. Growney,Mats Holmqvist,Meier Hsu,Daniel Jansson,Lei Jiang,Paul Kwon,Gang Liu,Franco Lombardo,Qiang Lu,Dyuti Majumdar,Christopher T. Meta,Lawrence Blas Perez,Minying Pu,Tim Ramsey,Remiszewski Stacy W,Suzanne Skolnik,Martin Traebert,Laszlo Urban,Vinita Uttamsingh,Ping Wang,Steven Whitebread,Lewis Whitehead,Yan Yan-Neale,Yung-Mae Yao,Liping Zhou,Peter Atadja +36 more
TL;DR: To determine if the observed cardiac effects of HDAC inhibitors in humans is due to hERG blockade, a highly potent HDAC inhibitor devoid of hERG activity was required and two compounds were discovered to be highly efficacious with weak affinity for the hERG and other ion channels.
69
The design, synthesis and structure-activity relationships of novel isoindoline-based histone deacetylase inhibitors.
Michael Shultz,Jianmei Fan,Chen Christine Hiu-Tung,Young Shin Cho,N Davis,Sheri Bickford,Kristen Buteau,Xueying Cao,Mats Holmqvist,Meier Hsu,Lei Jiang,Gang Liu,Qiang Lu,Chetan Patel,Joghee Raju Suresh,Mannangatti Selvaraj,Laszlo Urban,Ping Wang,Yan Yan-Neale,Lewis Whitehead,Haiyan Zhang,Liping Zhou,Peter Atadja +22 more
TL;DR: The design, synthesis and biological evaluation of a novel series of isoindoline-based hydroxamates, found to have greater in vitro anti-proliferative activity than several compounds in late stage clinical trials for the treatment of cancer, are described.
27
Lumiracoxib 400 mg Compared With Celecoxib 400 mg and Placebo for Treating Pain Following Dental Surgery: A Randomized, Controlled Trial
TL;DR: 400 mg lumiracoxib was well-tolerated and provided significantly superior analgesia to 400 mg celecoxib or placebo in patients with moderate-to-severe dental pain after surgical extraction of impacted molars.
13